Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Innovation Gives Pregnant Women with Diabetes Round-the-Clock Glucose Control

By Drug Discovery Trends Editor | April 27, 2015

Achieving better glucose control in pregnant women with diabetes by using continuous glucose monitoring may help them give birth to healthier children, new research from the University of Leeds said.

Up to 50 percent of babies born to women with diabetes are born too large, which can lead to greater intervention and problems during childbirth and also increase the risk of the child developing diabetes, obesity and cardiovascular disease later in life.

Usually, pregnant women with diabetes monitor their glucose during the day using the traditional ‘finger-prick’ test, which can be painful and inconvenient. However, only snapshots of what is happening to the glucose are picked up, as it is only done between four and eight times a day, and not at all during the night when asleep. 

Even when these blood glucose readings reach the targets required, pregnant women with diabetes still give birth to large babies. This suggests that the traditional finger-prick test may not be good enough to detect all the changes in glucose that contribute to the baby’s growth, and that using newer technology such as continuous glucose monitoring (CGM) may be able to help with this problem.

The research team, from the University of Leeds’ School of Medicine, has worked out a way to interpret the complex data provided by CGM devices, so they get a much clearer picture of the glucose control across the 24-hour day that is associated with having a large baby.

The devices usually consist of a tiny probe that sits just under the skin and a small data monitor that sits on the skin (about the size of a 50p piece), measuring glucose levels all day, every day, revealing in detail glucose changes that may otherwise be missed with finger-prick testing alone. 

Dr Eleanor Scott, Consultant in Diabetes and Endocrinology, who led the research with Dr Graham Law, Senior Lecturer in Statistical Epidemiology, said: “The reality is that comparing the data provided by a CGM to that offered by a finger-prick test is like comparing an image under the microscope to that seen by the naked eye – we get much more detail with CGM.

“Women can use this data to make sure that the times of day when glucose seems to run higher are periods where they are particularly careful to keep their glucose as close to normal as possible. They can do this by consulting with their ‘diabetes in pregnancy’ clinical teams who will be able to advise on timing of insulin, timing and types of food to help smooth the glucose profiles and avoid these problem areas.”

Dr Scott added that the next stage of the research would be to find out how its findings may help with the future design of the so-called “artificial pancreas”, the closed loop insulin systems which are being developed to transform the care of people with type 1 diabetes who are reliant on insulin. 

They consist of an integrated CGM sensor and insulin pump that talk to each other via computer to deliver insulin safely across the 24 hour day.

Dr Anna Secher, of the Center for Pregnant Women With Diabetes in the Department of Endocrinology at the University of Copenhagen, a collaborator on the study with the University of Cambridge, said: “CGM has been used for many years in The Center for Pregnant Women with Diabetes in Copenhagen, but this study is the first to investigate glucose levels ‘round the clock’ in relation to large babies.”

Source: University of Leeds


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE